Bio-Techne Corp at TD Cowen Healthcare Conference Transcript

Mar 03, 2026 / 04:10PM GMT
Release Date Price: MXN1090
Kyle Boucher
Cowen and Company LLC - Equity Analyst

All right. Good morning, everyone. Day 2 of the 46th Annual TD Cowen Healthcare Conference. I'm Kyle Boucher, an analyst on the life science and diagnostic tools team here. And I'm pleased to be joined by Kim Kelderman and Jim Hippel, CEO and CFO of Bio-Techne.

Kim and Jim, welcome to the conference.

Kim Kelderman
Bio-Techne Corp - President, Chief Executive Officer, Director

Thank you.

Questions & Answers

Kyle Boucher;Kim Kelderman
Cowen and Company LLC - Equity Analyst;Bio-Techne Corp

So today, I'd like to go through a number of questions, including the company's recent performance, the healthier end markets and then maybe get over to some of your growth pillars. But before we get into that, this year marks Bio-Techne's 50th anniversary. That's a big milestone. So I guess, Kim, maybe can you take a moment and just reflect on Techne's success to date and give a brief overview of your priorities going forward?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot